Ozempic, Wegovy or Mounjaro: Which Is Right for Me UK?

# Ozempic, Wegovy or Mounjaro: Which Is Right for Me UK?

Ozempic. Wegovy. Mounjaro. Three brand names that appear constantly in the same conversations about weight loss injections — and are consistently confused with each other, used interchangeably, and misunderstood even by people who are already taking one of them.

With the MHRA approving oral Wegovy (the Wegovy tablet) in June 2026, there is now a fourth option to understand: the same drug as Wegovy injection, but in a daily tablet format.

This guide cuts through the confusion. It explains what each product is, what it is actually licensed for in the UK, how they compare on weight loss outcomes and cost, and where the new Wegovy tablet fits in the picture.

> **Medical disclaimer:** Ozempic, Wegovy injection, Wegovy tablet, and Mounjaro are all prescription-only medicines. A clinical assessment by a qualified UK healthcare professional is required before any of these products can be prescribed. This guide is for informational purposes only and does not constitute medical advice or a recommendation to use any specific product.

—

## The quick answer: what each one actually is

Before the detailed comparison, here is the plain-English version:

– **Ozempic** = semaglutide injection, licensed in the UK for **type 2 diabetes** (not weight loss — though some prescribers use it off-label for weight management in specific circumstances)
– **Wegovy injection** = semaglutide injection, licensed in the UK for **weight management** — the same molecule as Ozempic, at a higher maximum dose, with a weight management licence
– **Wegovy tablet** = oral semaglutide, licensed in the UK for **weight management** — the same molecule as both of the above, in a daily tablet format, approved June 2026
– **Mounjaro** = tirzepatide injection, licensed in the UK for **type 2 diabetes** and **weight management** — a completely different drug from semaglutide, with a dual mechanism

The three brand names that come up most in weight loss conversations — Wegovy, Mounjaro, and Ozempic — are not the same product and do not work identically. The drug in Ozempic and both Wegovy products is semaglutide; the drug in Mounjaro is tirzepatide. These are different molecules.

—

## The detailed comparison

| | **Ozempic** | **Wegovy injection** | **Wegovy tablet** | **Mounjaro** |
|—|—|—|—|—|
| Active drug | Semaglutide | Semaglutide | Semaglutide | Tirzepatide |
| Format | Injection (weekly) | Injection (weekly) | Tablet (daily) | Injection (weekly) |
| UK licence | Type 2 diabetes | Weight management | Weight management | T2D + weight management |
| Maximum dose | 2mg | 2.4mg | 25mg | 15mg |
| Average weight loss (trials) | ~5–10% | ~20.7% | ~14–16% | ~20–22% |
| UK private price (approx.) | ~£80–150/month | ~£149–269/month | £64–£113.95/month | ~£159–268/month |
| NHS availability (June 2026) | Yes (type 2 diabetes) | Very restricted | Not yet | Yes (type 2 diabetes) |
| Fasting required | No | No | Yes — 30 min daily | No |
| Refrigeration needed | Yes | Yes | No | Yes |
| Needle required | Yes | Yes | No | Yes |

—

## Ozempic: what you need to know

Ozempic (semaglutide, Novo Nordisk) is licensed in the UK for type 2 diabetes management, not weight loss. It has been in clinical use since 2018 and has a strong safety and efficacy record for its licensed indication.

The weight loss conversation around Ozempic in the UK arose largely because it is the same active ingredient as Wegovy, but with a lower maximum dose and a diabetes licence. Some private prescribers have prescribed Ozempic off-label for weight management — this is technically legal in the UK but is not the standard of care. The correct product for weight management is Wegovy (either injection or, now, tablet), which carries the weight management licence and is available at the appropriate doses for that purpose.

**If you are seeking treatment for weight management:** Wegovy (injection or tablet) or Mounjaro are the appropriate first-line options to discuss with a prescriber. Ozempic is not a weight loss product and UK GPhC-registered providers should not be prescribing it as first-line weight management treatment.

**If you are on Ozempic for type 2 diabetes:** This is a separate clinical situation governed by your diabetes management plan. Any changes to your diabetes treatment must be made by the clinician managing that condition.

—

## Wegovy injection: the established weight loss option

Wegovy injection (semaglutide, Novo Nordisk) is the version most people are familiar with from the weight loss conversation. It is licensed for weight management in UK adults with a BMI of 30 or above (or 27+ with weight-related health conditions), and it has the strongest evidence base of any currently approved weight management medication for the injectable category of GLP-1 treatments.

STEP trial data showed approximately 20.7% average weight loss at maximum dose (2.4mg weekly) over 68 weeks. This is the benchmark against which the Wegovy tablet and Mounjaro are typically compared.

The injection is once weekly. It requires refrigeration. It is administered via a pre-filled pen injector at the start of treatment, with dose escalation over several months. UK private prices range from approximately £149 to £269 per month depending on provider and dose.

The Wegovy injection has been available in the UK since late 2023, and there is now a well-established network of GPhC-registered providers offering online assessments and prescriptions.

—

## Wegovy tablet: the new option (June 2026)

Wegovy tablet (oral semaglutide, Novo Nordisk) was approved by the MHRA on 11 June 2026. It is the same active ingredient as the Wegovy injection — semaglutide — but in a once-daily tablet format.

The tablet doses are 1.5mg, 4mg, 9mg, and 25mg. These numbers are much higher than the injection doses (0.25mg to 2.4mg) because the tablet has much lower bioavailability — only approximately 1–2% of oral semaglutide is absorbed compared to approximately 89% for the injection. The doses are higher to compensate.

OASIS trial data showed approximately 14–16% average weight loss at maximum tablet dose, compared to ~20.7% for the injection. The tablet is somewhat less effective on average — but it has significant practical advantages: no needle, no refrigeration, no sharps disposal, no injection anxiety, and a starting price of £64 per month — substantially cheaper than the injection.

**The tablet requires a 30-minute morning fasting window** on waking, before eating or drinking anything except 120ml of plain still water. This is non-negotiable and is the main lifestyle adjustment the tablet demands.

The Wegovy tablet is the newest and cheapest entry point into semaglutide-based weight management in the UK.

—

## Mounjaro: the different drug

Mounjaro (tirzepatide, Eli Lilly) is a completely different drug from semaglutide. It is a dual agonist that activates both the GLP-1 receptor and the GIP receptor simultaneously. This dual mechanism produces greater insulin secretion and more significant appetite suppression in many people than GLP-1-only drugs.

SURMOUNT trial data showed approximately 20–22% average weight loss at maximum dose (15mg weekly), giving Mounjaro a modest but consistent efficacy advantage over the Wegovy injection in head-to-head data comparisons. It is not head-to-head with the Wegovy tablet — but comparing the trial data, Mounjaro produces substantially more weight loss on average than the tablet.

Mounjaro is injection-only — there is no oral tirzepatide product currently approved in the UK. It requires refrigeration, weekly injection, and sharps disposal. UK private prices range from approximately £159 to £268 per month.

Mounjaro is licensed in the UK for both type 2 diabetes and weight management (the latter via its Zepbound licence, available under the Mounjaro brand from licensed providers for weight management).

—

## Where the Wegovy tablet fits in the landscape

The Wegovy tablet occupies a specific and clear position:

– It is the **only needle-free option** for semaglutide-based weight management currently available in the UK
– It is the **most affordable** entry point into GLP-1 weight management treatment, starting at £64/month
– It has a **lower effectiveness ceiling** than either the Wegovy injection or Mounjaro in clinical trial data
– It requires the **daily fasting routine** that neither the injection nor Mounjaro requires

For people who want the benefits of semaglutide without needles, without refrigeration, and at the lowest possible cost — the tablet is the right choice. For people for whom maximum weight loss is the priority and needles are manageable, the injection or Mounjaro may produce better outcomes.

—

## A note on Ozempic prescribed for weight loss

You may encounter private providers offering Ozempic for weight loss in the UK. While this is not illegal, it is off-label use of a diabetes medication. The GPhC expects registered pharmacies to follow appropriate prescribing standards, and the appropriate products for weight management are Wegovy (either format) or Mounjaro (for those who meet the criteria).

If you are being offered Ozempic specifically for weight loss rather than Wegovy, it is worth asking the provider why Ozempic is being prescribed rather than the licensed weight management product. In many cases the reason is cost or supply — Ozempic may be cheaper or more readily available. A good provider will explain their clinical reasoning clearly.

—

## Frequently asked questions

### Is Ozempic the same as Wegovy?

They contain the same active ingredient — semaglutide — but they are different products. Ozempic is licensed for type 2 diabetes in the UK, with a maximum dose of 2mg weekly. Wegovy is licensed for weight management, with a maximum dose of 2.4mg (injection) or 25mg (tablet). Wegovy’s higher dose ceiling and weight management licence make it the appropriate product for non-diabetic weight loss treatment.

### Can my GP switch me from Ozempic to the Wegovy tablet?

If you are currently on Ozempic for type 2 diabetes, any change to your diabetes treatment must be discussed with the clinician managing that condition — this is not a decision to make independently or through a private weight management provider. If you are on Ozempic for off-label weight management, speak to your prescriber about whether the Wegovy tablet would be more appropriate for your goals.

### Which is cheapest — Ozempic, Wegovy, or Mounjaro?

For weight management treatment, the Wegovy tablet is currently the most affordable option in the UK, starting from £64 per month. Wegovy injection and Mounjaro are broadly comparable in price (£149–£269/month), with significant variation by provider and dose. Ozempic private prices vary widely and depend on the dose.

### Does the NHS cover any of these treatments?

As of June 2026: Ozempic is available on the NHS for type 2 diabetes. Mounjaro is available on the NHS for type 2 diabetes. Wegovy injection is technically approved for NHS use but access is extremely restricted — almost no NHS patients receive it currently. The Wegovy tablet is not yet available on the NHS. Most patients accessing these treatments for weight management are doing so privately.

### Is Mounjaro better than Wegovy for weight loss?

In clinical trial data, Mounjaro (tirzepatide) produces slightly higher average weight loss than the Wegovy injection (~20–22% vs ~20.7%), and substantially higher than the Wegovy tablet (~14–16%). However, Mounjaro requires injection, refrigeration, and costs significantly more than the Wegovy tablet. For people for whom needle-free treatment and cost are priorities, the Wegovy tablet may be the better practical choice even though Mounjaro has a higher effectiveness ceiling. This is a decision to make with your prescriber, with full information about both options.

—

*This article is for informational purposes only and does not constitute medical advice. Ozempic, Wegovy (injection and tablet), and Mounjaro are prescription-only medicines available in the UK. Always consult a registered UK healthcare professional before starting or changing treatment, and follow the patient information leaflet supplied with your medication. CompareWegovyPrices.co.uk is not affiliated with Novo Nordisk or Eli Lilly.*